Immunomedics announced the availability of Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease. Trodelvy is the first antibody-drug conjugate to get FDA approval for this indication.
Trodelvy is administered via intravenous infusion after reconstitution and dilution. Premedication is recommended to prevent infusion reactions and chemotherapy-induced nausea and vomiting. Patients should be monitored during the infusion and for at least 30 minutes after completion.
Regarding safety, Trodelvy carries a Boxed Warning for the risk of severe neutropenia and diarrhea. The most common adverse reactions associated with therapy include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, and abdominal pain. Dose reduction or treatment interruption may be needed to manage adverse reactions.
“We want all eligible mTNBC patients, who have had at least 2 prior therapies, to have the opportunity to benefit from Trodelvy as a new treatment,” said Brendan Delaney, Chief Commercial Officer of Immunomedics. “In so doing, we hope to establish Immunomedics as a trusted and differentiated partner within the breast cancer community.”
Trodelvy is supplied as 180mg of sacituzumab govitecan-hziy in single-dose vials. The product is distributed via specialty pharmacies; a savings program is available for commercially or privately insured patients.
Trodelvy is not a substitute and should not be used with other drugs containing irinotecan or its active metabolite SN-38.
For more information visit trodelvy.com.
This article originally appeared on MPR